The stock's fall snapped a four-day winning streak.

We came across a bullish thesis on Merck & Co., Inc. (MRK) on Value Investing Subreddit Page by CompanyCharts. In this ...

Shares fell after the company cut its full-year guidance on the back of challenging macroeconomic conditions and ...

Pfizer beats EPS estimates for the 12th quarter. Explore PFE's oncology success, cost-cutting impact, and why it's rated a ...

Despite Merck KGaA’s lupus drug failing to prove itself against one form of the autoimmune disease, the German drugmaker has ...

The Swiss pharma has inked several collaborations in this field, suggesting it sees the approach as promising to rid the body ...

We recently published a list of the 20 Best Dividend Growth Stocks with High Yields. In this article, we are going to take a ...

Phase 3 clinical trial of BNC-210 in social anxiety disorder on track for topline readout in Q3 2025α7 nicotinic ...

Having already worked with clinical trial sites in more than 14 states, CTAC will now take its work nationwide, the ...

Merck & Co – known as MSD outside the US and Canada – has received approval from the Medicines and Healthcare products ...

Pfizer, on the other hand, with its improving growth prospects, rising estimates, cheaper valuation, and higher dividend ...

Merck (MRK) stock gains as its bestselling drug, Keytruda, as part of a combination regimen, succeeds in a Phase 3 trial for ...